SSA
MTNB icon

Schonfeld Strategic Advisors’s Matinas BioPharma MTNB Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-251
Closed -$13K – 2171
2021
Q1 		$13K Buy
+251
New +$16.8K ﹤0.01% 1745
2019
Q3 		– Sell
-1,068
Closed -$46K – 1159
2019
Q2 		$46K Sell
1,068
-898
-46% -$43.2K ﹤0.01% 943
2019
Q1 		$107K Buy
+1,966
New +$106K ﹤0.01% 989

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Schonfeld Strategic Advisors's MTNB Position: Q2 2021 in Review

Schonfeld Strategic Advisors sold out of Matinas BioPharma (MTNB) in Q2 2021, closing a stake of 251 shares — an estimated $13K sold.

Schonfeld Strategic Advisors first reported a position in MTNB in Q1 2019 and held it in 3 quarters. The position peaked at $107K in Q1 2019. 67 funds tracked by Wall St. Rank hold MTNB as of Q2 2021.

  • Schonfeld Strategic Advisors reported no remaining Matinas BioPharma position as of Q2 2021 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 251 Matinas BioPharma shares in Q2 2021, an estimated $13K.
  • Schonfeld Strategic Advisors first reported a position in Matinas BioPharma in Q1 2019 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Matinas BioPharma position peaked at $107K in Q1 2019.
  • 67 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.